DHR · Earnings call · 2026Q3T · Full report

Geographic Revenue Performance

DANAHER CORP /DE/ · 2026-10-21 · Importance null · Surprise 40

Developed-market core revenue was flat, with Western Europe growing mid-single digits and North America declining low single digits, primarily because of lower respiratory revenue. High-growth markets grew approximately 10%, with healthy growth across all major regions. China was up high single digits, with growth in Biotechnology, Life Sciences, and Diagnostics. Management attributed support in China’s Biotechnology and Life Sciences businesses to healthier funding and investment levels, while Diagnostics continued to move beyond the largest effects of healthcare policy changes.

Key facts

• Danaher’s high-growth-market core revenues increased approximately 10% in Q3 2026, with healthy growth across all major regions.
• Danaher’s China core revenues grew high single digits in Q3 2026, with growth in all three segments.
• Danaher’s developed-market core revenues were flat in Q3 2026; Western Europe grew mid-single digits and North America declined low single digits, primarily due to lower respiratory revenue.